ReviewCNS drugs2005
COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date.
Review in CNS drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Efficacy and safety of celecoxib in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2025Pooled it
- Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.Schizophrenia bulletin · 2009Pooled it
- Does Systemic Inflammation Play a Role in Pediatric Psychosis?Clinical schizophrenia & related psychoses · 2015Article
- Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders.Current neuropharmacology · 2015Review
- Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.Psychiatry research · 2012Article
- Identification of blood biomarkers for psychosis using convergent functional genomics.Molecular psychiatry · 2011Article
- The pipeline and future of drug development in schizophrenia.Molecular psychiatry · 2007Review
- A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
- Rationale for a trial of immunosuppressive therapy in acute schizophrenia.Molecular psychiatry · 2007Review
- Caspase 1 deficiency reduces inflammation-induced brain transcription.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.